COMMUNIQUÉS West-GlobeNewswire

Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
11/07/2025
Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/07/2025
WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
4DMT Announces New Employment Inducement Grants
11/07/2025
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
11/07/2025
JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has [...]
Clarification on Leadership Announcement: Annette Slyman not to join Life Backup Plan as Chief Operating Officer
11/07/2025
Aliso Viejo, CA, July 11, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., the developer of the Life Backup Plan app, is issuing a clarification to our July 10, 2025 press release. Annette Slyman will not be joining the team in [...]
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
11/07/2025
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust and biomarker data [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/07/2025
CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
11/07/2025
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from [...]
Safest Steroid for Muscle Growth and Bodybuilding - Clinical Evidence and Safety Behind CrazyBulk's Bulking Steroids
11/07/2025
New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) -- For decades, the use of muscle building steroids has been a driving force behind the pursuit of muscle growth and physical prowess among bodybuilders, athletes, and [...]
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
11/07/2025
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative [...]
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
11/07/2025
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – [...]
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award
11/07/2025
Award Recognition underscores the importance of AI-driven drug discovery VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), [...]
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
11/07/2025
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today published a new peer- [...]
Valneva annonce la levée de la restriction temporaire de l'Agence européenne des médicaments sur l'utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées
11/07/2025
Saint Herblain (France), le 11 juillet 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence [...]
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
11/07/2025
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on [...]
Milestone Pharmaceuticals Announces Proposed Public Offering
11/07/2025
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering [...]
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
11/07/2025
FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated [...]
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
11/07/2025
CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
11/07/2025
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company [...]

Pages